Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer

June 14, 2022 11:57 am

by Lindsey Fischer

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Patients with ovarian cancer treated with FDA-approved

Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

New drug shows promise slowing tumor growth in some hard-to-treat cancers

April 29, 2022 2:06 pm

by Amanda Ferguson

Daniel Durocher’s lab designed a new drug with CRISPR-Cas9 gene-editing technology that blocks an enzyme essential for the survival of certain cancer cells (photo courtesy of Sinai Health

Scientists at Sinai Health and the University of Toronto … Read more

Break Through Cancer Announces $50 Million in Grants to Researchers From Five Top Cancer Research Centers

April 19, 2022 9:13 am

by the ASCO Post Staff

Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more

Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer

April 13, 2022 2:12 pm

by Conor Killmurray

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

The use of dual immune checkpoint

Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

Novel metabolic mechanisms contribute to how ovarian cancer evades immune attack, research finds

March 16, 2022 9:43 am

by Emily Henderson, B.Sc.

High-grade serous carcinoma is the most aggressive form of ovarian cancer and accounts for the majority of advanced-stage cases. The poor outcomes associated with the disease underscore the need for more effective treatments. A research team … Read more

‘Drug factory’ implants eliminate ovarian, colorectal cancer in mice

March 2, 2022 11:45 am

by Jade Boyd

Rice immunotherapy treatment could begin human clinical trials this year

HOUSTON – (March 2, 2022) – Rice University bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days

Read more

Could Pap smears one day help detect breast and ovarian cancers?

February 1, 2022 5:33 pm

by Angus Chen

New research suggests that cervical cancer screenings could be used to pick up on a patient’s risk of breast, ovarian, and endometrial cancers.

Routine screenings have become a powerful tool in catching cervical cancer as early … Read more

MCW scientists uncover potential therapeutic target and biomarker for ovarian cancerPortfolio Inspiration

November 17, 2021 11:28 am

MEDICAL COLLEGE OF WISCONSIN

The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer

Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more

How ovarian cancers evade the immune system

October 6, 2021 12:00 am

By Krista Conger

It’s diabolical, and so clever. Recent research by cancer biologist Wendy Fantl, PhD, and immunologist and cancer biologist Veronica Gonzalez, PhD, shows that ovarian tumors thrive by convincing nearby immune cells that the cancer cells are those … Read more

Women with genetic mutations fare no worse with breast or ovarian cancer, study finds

October 1, 2021 12:00 am

By Krista Conger

Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.

Women newly diagnosed with breast or ovarian cancer who are also … Read more

Third COVID Vaccine Dose Boosts Protection in Solid Tumor Patients

October 1, 2021 12:00 am

By Mike Bassett

— For those on active therapy, 80% had increased antibody levels, study showed

A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as … Read more

What Patients With Ovarian Cancer Should Know About Maintenance Therapy

September 29, 2021 10:05 am

By Jamie Cesanek

Maintenance therapy is meant to prevent relapse after a patient with ovarian cancer received their main treatment. Here’s an overview of what patients should know.

When a patient is diagnosed with ovarian cancer, their initial treatment typically

Read more

Symptoms of Ovarian Cancer Explained as Woman Diagnosed Thanks to Small Navel Growth

September 28, 2021 12:00 am

By Aatif Sulleyman

A woman is raising awareness of ovarian cancer and how difficult it can be to detect, having been diagnosed with the illness by a dermatologist who removed a small growth from her navel.

Despite being aware of … Read more

Wistar Scientists Identify New Therapeutic Target in Ovarian Cancer Subtype With Poor Prognosis. Ovarian clear cell carcinomas with ARID1A mutations are sensitive to inhibition of the IRE1a-XBP1 stress response pathway in preclinical models.

September 21, 2021 5:12 pm

By Wistar Institute

Newswise — PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered … Read more

Two Pathways, One Destination: Promising Drug Combination to Treat Ovarian Cancer

March 15, 2021 3:00 pm

By R. Colon-Thillet

Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3, 2021 4:00 pm

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

By Courtney Marabella

The FDA has granted priority review to the new

Read more

Most Patients With Breast, Ovarian Cancer Patients Do Not Undergo Genetic Testing

March 1, 2021 7:00 pm

By Christina Bennett, MS

The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing.  Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more